L2 Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

L2 Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.6M	Buy	45,073 +19,933	+79%	+$1.14M	0.27%	84
2026 Q1	$1.52M	Buy	25,140 +14,376	+134%	+$838K	0.15%	130
2025 Q4	$581K	Buy	10,764 +2,194	+26%	+$106K	0.08%	200
2025 Q3	$387K	Sell	8,570 -446	-5%	-$20.8K	0.06%	244
2025 Q2	$417K	Sell	9,016 -11,384	-56%	-$559K	0.07%	230
2025 Q1	$1.24M	Buy	20,400 +1,957	+11%	+$114K	0.25%	85
2024 Q4	$1.04M	Buy	18,443 +3,304	+22%	+$185K	0.23%	89
2024 Q3	$783K	Buy	15,139 +426	+3%	+$20K	0.21%	82
2024 Q2	$611K	Buy	14,713 +8,428	+134%	+$377K	0.18%	96
2024 Q1	$341K	Buy	+6,285	New	+$320K	0.11%	142
2023 Q4	–	Sell	-977	Closed	-$969K	–	185
2023 Q3	$969K	Sell	977 -21,190	-96%	-$1.3M	0.46%	62
2023 Q2	$1.34M	Sell	22,167 -38,838	-64%	-$2.6M	0.66%	51
2023 Q1	$4.23M	Buy	61,005 +11,656	+24%	+$822K	2.33%	8
2022 Q4	$3.55M	Buy	49,349 +618	+1%	+$46.6K	2.21%	11
2022 Q3	$3.46M	Buy	48,731 +8,582	+21%	+$623K	2.38%	8
2022 Q2	$3.09M	Buy	40,149 +27,977	+230%	+$2.13M	2.24%	7
2022 Q1	$889K	Buy	12,172 +6,916	+132%	+$464K	0.51%	61
2021 Q4	$328K	Buy	+5,256	New	+$308K	0.23%	90
2021 Q3	–	Sell	-3,644	Closed	-$243K	–	62
2021 Q2	$243K	Sell	3,644 -342	-9%	-$22.3K	0.23%	83
2021 Q1	$252K	Sell	3,986 -5,395	-58%	-$336K	0.26%	76
2020 Q4	$582K	Sell	9,381 -2,386	-20%	-$147K	0.4%	62
2020 Q3	$709K	Buy	+11,767	New	+$708K	0.57%	49

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

L2 Asset Management's BMY Position: Q2 2026 in Review

L2 Asset Management increased its Bristol-Myers Squibb (BMY) stake by 79% in Q2 2026, buying an estimated $1.14M and bringing the position to 45,073 shares worth $2.6M. The position accounts for 0.27% of the portfolio, ranked #84.

L2 Asset Management first reported a position in BMY in Q3 2020 and has held it in 22 quarters since. The position peaked at $4.23M in Q1 2023. 2,523 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

L2 Asset Management held 45,073 shares of Bristol-Myers Squibb worth $2.6M as of Q2 2026.
L2 Asset Management bought 19,933 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.14M.
Bristol-Myers Squibb made up 0.27% of L2 Asset Management's portfolio in Q2 2026, its #84 holding.
L2 Asset Management first reported a position in Bristol-Myers Squibb in Q3 2020 and has held it in 22 quarters since.
L2 Asset Management's Bristol-Myers Squibb position peaked at $4.23M in Q1 2023.
2,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on L2 Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.